Octreotide
- Generic Name
- Octreotide
- Brand Names
- Bynfezia, Mycapssa, Sandostatin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83150-76-9
- Unique Ingredient Identifier
- RWM8CCW8GP
- Background
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threat...
- Indication
Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide an...
- Associated Conditions
- Acromegaly, Diarrhea, Metastatic Carcinoid Tumors
- Associated Therapies
- Long-term maintenance therapy
Outcome of ADPKD With Octreotide LAR
- Conditions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 70
- Registration Number
- NCT06193616
- Locations
- 🇮🇹
ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Target Recruit Count
- 62
- Registration Number
- NCT06085976
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Spain
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT05477576
- Locations
- 🇪🇸
Research Facility, Zaragoza, Spain
Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 184
- Registration Number
- NCT05199038
Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 36
- Registration Number
- NCT04353193
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2019-10-25
- Target Recruit Count
- 10
- Registration Number
- NCT04140409
Angiotensin 2 for Hepatorenal Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT04048707
Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT04028323
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China
Palliative Management of Inoperable Malignant Bowel Obstruction
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT04027348
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 1682
- Registration Number
- NCT03846180
- Locations
- 🇨🇳
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Department of Gastroenterology, Air Force Hospital of Northern Theater Command, Shenyang, Liaoning, China
🇨🇳Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.